BioNTech Future Growth
Future criteria checks 0/6
BioNTech is forecast to grow earnings and revenue by 12.4% and 3.4% per annum respectively. EPS is expected to grow by 10.6% per annum. Return on equity is forecast to be -2% in 3 years.
Key information
12.4%
Earnings growth rate
10.6%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 3.4% |
| Future return on equity | -2.0% |
| Analyst coverage | Good |
| Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,599 | -787 | -1,021 | -1,024 | 14 |
| 12/31/2025 | 2,602 | -813 | 179 | -601 | 19 |
| 12/31/2024 | 2,616 | -765 | 468 | 761 | 17 |
| 9/30/2024 | 3,040 | -467 | 971 | 1,522 | N/A |
| 6/30/2024 | 2,691 | -504 | 2,352 | 2,972 | N/A |
| 3/31/2024 | 2,730 | 113 | 4,944 | 5,732 | N/A |
| 12/31/2023 | 3,819 | 930 | 4,666 | 5,371 | N/A |
| 9/30/2023 | 6,618 | 2,751 | 4,690 | 5,350 | N/A |
| 6/30/2023 | 9,184 | 4,375 | 8,726 | 9,317 | N/A |
| 3/31/2023 | 12,213 | 6,238 | 8,493 | 8,850 | N/A |
| 12/31/2022 | 17,311 | 9,434 | 13,214 | 13,577 | N/A |
| 9/30/2022 | 18,565 | 10,322 | 12,277 | 12,549 | N/A |
| 6/30/2022 | 21,191 | 11,748 | 9,040 | 9,271 | N/A |
| 3/31/2022 | 23,303 | 12,863 | 5,066 | 5,251 | N/A |
| 12/31/2021 | 18,977 | 10,293 | 736 | 890 | N/A |
| 9/30/2021 | 13,790 | 7,493 | 1,198 | 1,338 | N/A |
| 6/30/2021 | 7,770 | 4,072 | -474 | -355 | N/A |
| 3/31/2021 | 2,503 | 1,197 | -376 | -270 | N/A |
| 12/31/2020 | 482 | 15 | -99 | -13 | N/A |
| 9/30/2020 | 165 | -410 | -382 | -326 | N/A |
| 6/30/2020 | 126 | -230 | -239 | -183 | N/A |
| 3/31/2020 | 110 | -192 | -268 | -222 | N/A |
| 12/31/2019 | 109 | -179 | -270 | -198 | N/A |
| 9/30/2019 | 144 | -122 | -220 | -138 | N/A |
| 6/30/2019 | 136 | -116 | -142 | -75 | N/A |
| 3/31/2019 | 132 | -77 | -136 | -55 | N/A |
| 12/31/2018 | 128 | -48 | -126 | -59 | N/A |
| 12/31/2017 | 62 | -86 | N/A | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 22UA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 22UA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 22UA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 22UA's revenue (3.4% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 22UA's revenue (3.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 22UA is forecast to be unprofitable in 3 years.